Immune-Related Adverse Events of a PD-(L)1 Inhibitor Plus Chemotherapy Versus a PD-(L)1 Inhibitor Alone in First-Line Treatment for Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Control Trials

摘要

Background: The addition of chemotherapy to a programmed death 1/programmed death ligand 1 (PD-(L)1) inhibitor is a more effective option as a first-line treatment for advanced non-small cell lung cancer (NSCLC). It might also inhibit an overactive immune response and thereby reduce immune-related adverse events (irAEs). This meta-analysis assessed the rate of irAEs with a PD-(L)1 inhibitor plus chemotherapy (I+C) versus a PD-(L)1 inhibitor alone (I) and evaluated the indirect relative risk (RR) of I+C versus I.